Subscribe
igorua-shutterstock-com-patent-
IgorUA / Shutterstock.com
22 December 2020AmericasMuireann Bolger

US Congress confirms new drug patent listing law

A $2.3 trillion spending bill passed by the  US Congress yesterday, December 21 includes a proposed change to the laws concerning biologic drugs.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Diabetics to benefit under latest FDA biosimilar guidance
13 May 2019   The Food and Drug Administration has issued final guidance on the pathway for ‘interchangeable’ biosimilar products, in a bid to promote competition in the biologics market.
Americas
AstraZeneca asks FDA to delay ANDAs for Crestor generics
14 June 2016   AstraZeneca has filed a citizen petition to the US Food and Drug Administration requesting it to wait until 2023 before approving generic versions of Crestor, a cholesterol treatment.


Editor's picks

UKIPO rejects Boehringer’s SPC for horse inhaler
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

Editor's picks

Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

More on this story

Americas
Diabetics to benefit under latest FDA biosimilar guidance
13 May 2019   The Food and Drug Administration has issued final guidance on the pathway for ‘interchangeable’ biosimilar products, in a bid to promote competition in the biologics market.
Americas
AstraZeneca asks FDA to delay ANDAs for Crestor generics
14 June 2016   AstraZeneca has filed a citizen petition to the US Food and Drug Administration requesting it to wait until 2023 before approving generic versions of Crestor, a cholesterol treatment.

More on this story

Americas
Diabetics to benefit under latest FDA biosimilar guidance
13 May 2019   The Food and Drug Administration has issued final guidance on the pathway for ‘interchangeable’ biosimilar products, in a bid to promote competition in the biologics market.
Americas
AstraZeneca asks FDA to delay ANDAs for Crestor generics
14 June 2016   AstraZeneca has filed a citizen petition to the US Food and Drug Administration requesting it to wait until 2023 before approving generic versions of Crestor, a cholesterol treatment.

More features

Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’
Powell Gilbert launches Düsseldorf office with leading patent litigator
Startups toolkit: Why investors want more than patents
J&J fends off generic schizophrenia drug bids
Kilpatrick adds ‘seasoned litigator’ as trademark partner
WATCH: An update on EPO Board of Appeal strategy for 2025 and beyond
Startup challenges rival over brain monitoring tech at ITC
UKIPO rejects Boehringer’s SPC for horse inhaler